Cambrex Unveils New Liquid-Phase Peptide Synthesis Technology
Friday, September 20, 2024
Cambrex has announced that its subsidiary, Snapdragon Chemistry, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology.
The new LPPS technology significantly reduces solvent consumption and the use of excess reagents, offering a more sustainable alternative to traditional solid-phase peptide synthesis methods.
The technology supports peptides up to 12 residues in length, with larger peptides being assembled using a convergent fragment coupling approach in the liquid phase. Additionally, the LPPS process can be scaled similarly to traditional small molecule synthesis.
This approach can enhance product quality and stability while reducing the reliance on preparative chromatography and lyophilisation.
Snapdragon Chemistry, based in Waltham, Massachusetts, specialises in API batch and continuous flow process development, offering state-of-the-art automation technology and proprietary equipment to address challenging process and analytical development needs.
This innovation utilises standard active pharmaceutical ingredient (API) batch reactors and continuous flow processes, eliminating the need for specialised solid-phase reactors.
Cambrex has also advanced its capabilities in peptide and protein crystallisation, developing a crystallisation screening platform that helps identify crystalline forms of peptides and proteins.
The company continues to invest in research and development across complex synthetic modalities, including further advancements in peptide technologies and new research into the application of artificial intelligence for optimising oligonucleotide processes.
Source: cambrex.com
